Altimmune Statement On The Passing Of Dr. Stephen Harrison


(MENAFN- GlobeNewsWire - Nasdaq) GAITHERSBURG, Md., April 25, 2024 (GLOBE NEWSWIRE) -- The Altimmune team would like to express our sorrow and extend our heartfelt condolences to Dr. Stephen Harrison's family following his tragic and unexpected passing.

Dr. Harrison's countless contributions to advancing needed treatments for metabolic liver disease will leave a profound and lasting legacy throughout our field, with his patients and the people engaged in understanding and treating liver disease. His brilliance and vision were only rivaled by his eloquence, charisma and steadfast commitment to improving the lives of people with liver disease. He was a tireless advocate for patients and a deeply respected advisor, investigator and friend to Altimmune.

We will miss him greatly as we adjust to this tremendous loss for the community. We honor his memory and are grateful for having known and worked with him.

Contact:
Rich Eisenstadt
Chief Financial Officer
Phone: 240-654-1450
...


MENAFN25042024004107003653ID1108140845


GlobeNewsWire - Nasdaq

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.